| Dr Zubin G Khubchandani, MD | |
|
815 Ira E Woods Ave, Ste 100, Grapevine, TX 76051-4012 | |
| (817) 421-0505 | |
| (817) 421-6060 |
| Full Name | Dr Zubin G Khubchandani |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 28 Years |
| Location | 815 Ira E Woods Ave, Grapevine, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508891458 | NPI | - | NPPES |
| 0054LS | Other | TX | BC/BS |
| 3003838 | Other | TX | AETNA |
| 4089613 | Other | TX | HEALTHMARKET |
| 172659801 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | L4493 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Medical Center At Trophy Club | Trophy club, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Institute Of Orthopedic Surgery And Sports Medicine Pllc | 0840474037 | 4 |
News Archive
Patients with atrial fibrillation (AF) who need anticoagulation before undergoing electrical correction of their abnormal heartbeat (cardioversion) may benefit from treatment with edoxoban - a non-vitamin K antagonist (VKA) oral anticoagulant (NOAC), according to results of the ENSURE-AF trial.
Mayo Clinic researchers have developed a new way to assess a common cause of chronic diarrhea, microscopic colitis, using the Microscopic Colitis Disease Activity Index.
Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. The team synthesized the 1.08 million base pair chromosome of a modified Mycoplasma mycoides genome.
A new study reports successful immunization against a so-far invincible "death star" strain of an HIV-related laboratory virus (SIVmac239) and another tough strain. The new approach also achieves long-term protection with a single dose, showing that gene therapy could allow broad and durable protection, based on a modified form of the CD4 protein that allows HIV entry into human cells.
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
› Verified 4 days ago
| Entity Name | Texas Institute Of Orthopedic Surgery & Sports Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356484638 PECOS PAC ID: 0840474037 Enrollment ID: O20110413000220 |
News Archive
Patients with atrial fibrillation (AF) who need anticoagulation before undergoing electrical correction of their abnormal heartbeat (cardioversion) may benefit from treatment with edoxoban - a non-vitamin K antagonist (VKA) oral anticoagulant (NOAC), according to results of the ENSURE-AF trial.
Mayo Clinic researchers have developed a new way to assess a common cause of chronic diarrhea, microscopic colitis, using the Microscopic Colitis Disease Activity Index.
Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. The team synthesized the 1.08 million base pair chromosome of a modified Mycoplasma mycoides genome.
A new study reports successful immunization against a so-far invincible "death star" strain of an HIV-related laboratory virus (SIVmac239) and another tough strain. The new approach also achieves long-term protection with a single dose, showing that gene therapy could allow broad and durable protection, based on a modified form of the CD4 protein that allows HIV entry into human cells.
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zubin G Khubchandani, MD 815 Ira E Woods Ave, Ste 100, Grapevine, TX 76051-4012 Ph: (817) 421-0505 | Dr Zubin G Khubchandani, MD 815 Ira E Woods Ave, Ste 100, Grapevine, TX 76051-4012 Ph: (817) 421-0505 |
News Archive
Patients with atrial fibrillation (AF) who need anticoagulation before undergoing electrical correction of their abnormal heartbeat (cardioversion) may benefit from treatment with edoxoban - a non-vitamin K antagonist (VKA) oral anticoagulant (NOAC), according to results of the ENSURE-AF trial.
Mayo Clinic researchers have developed a new way to assess a common cause of chronic diarrhea, microscopic colitis, using the Microscopic Colitis Disease Activity Index.
Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. The team synthesized the 1.08 million base pair chromosome of a modified Mycoplasma mycoides genome.
A new study reports successful immunization against a so-far invincible "death star" strain of an HIV-related laboratory virus (SIVmac239) and another tough strain. The new approach also achieves long-term protection with a single dose, showing that gene therapy could allow broad and durable protection, based on a modified form of the CD4 protein that allows HIV entry into human cells.
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
› Verified 4 days ago
Dr. Eric Matthew Stehly, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2535 Ira E Woods Ave, Grapevine, TX 76051 Phone: 817-481-2121 Fax: 817-488-4493 | |
Dr. Michael Ryan Briseno, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2535 Ira E Woods Ave, Grapevine, TX 76051 Phone: 817-481-2121 Fax: 817-488-4493 | |
Dr. Scott Wenger, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 815 Ira E Woods Ave, Ste 100, Grapevine, TX 76051 Phone: 817-421-0505 Fax: 817-421-6060 | |
Dr. Amir M Khan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 815 Ira E Woods Ave, Ste 100, Grapevine, TX 76051 Phone: 817-421-0505 Fax: 817-421-6060 | |
Dr. Kristen Elizabeth Fleager, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2535 Ira E Woods Ave, Grapevine, TX 76051 Phone: 817-481-2121 Fax: 817-488-4493 | |
Dr. Pat Andrew Peters, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2535 Ira E Woods Ave, Grapevine, TX 76051 Phone: 817-481-2121 Fax: 817-488-4493 | |
Mr. Jeffrey Dean Moffett, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2535 Ira E Woods Ave, Grapevine, TX 76051 Phone: 817-481-2121 Fax: 817-488-4493 |